Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Sirt1 protects from K-Ras-driven lung carcinogenesis.

Costa-Machado LF, Martín-Hernández R, Sanchez-Luengo MÁ, Hess K, Vales-Villamarin C, Barradas M, Lynch C, de la Nava D, Diaz-Ruiz A, de Cabo R, Cañamero M, Martinez L, Sanchez-Carbayo M, Herranz D, Serrano M, Fernandez-Marcos PJ.

EMBO Rep. 2018 Sep;19(9). pii: e43879. doi: 10.15252/embr.201643879. Epub 2018 Jul 18.

PMID:
30021836
2.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. Review.

PMID:
29496372
3.

The metastasis suppressor KISS1 is an intrinsically disordered protein slightly more extended than a random coil.

Ibáñez de Opakua A, Merino N, Villate M, Cordeiro TN, Ormaza G, Sánchez-Carbayo M, Diercks T, Bernadó P, Blanco FJ.

PLoS One. 2017 Feb 16;12(2):e0172507. doi: 10.1371/journal.pone.0172507. eCollection 2017.

4.

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.

Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA.

Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Review.

PMID:
27641313
5.

Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer.

Pompas-Veganzones N, Sandonis V, Perez-Lanzac A, Beltran M, Beardo P, Juárez A, Vazquez F, Cozar JM, Alvarez-Ossorio JL, Sanchez-Carbayo M.

Tumour Biol. 2016 Oct;37(10):14301-14310. Epub 2016 Sep 3.

PMID:
27592258
6.

Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis through p16-Independent Mechanisms.

De Faveri LE, Hurst CD, Roulson JA, Wood H, Sanchez-Carbayo M, Knowles MA, Chapman EJ.

Transl Oncol. 2015 Oct;8(5):387-99. doi: 10.1016/j.tranon.2015.08.002.

7.

Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.

Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ.

Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Review.

PMID:
25306288
8.

Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice.

van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, Shariat SF, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeney LA.

Urol Oncol. 2014 Oct;32(7):1078-87. doi: 10.1016/j.urolonc.2014.07.002. Epub 2014 Sep 10. Review.

PMID:
25217465
9.

Molecular classification of non-muscle-invasive bladder cancer (pTa low-grade, pT1 low-grade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes.

Sacristan R, Gonzalez C, Fernández-Gómez JM, Fresno F, Escaf S, Sánchez-Carbayo M.

J Mol Diagn. 2014 Sep;16(5):564-572. doi: 10.1016/j.jmoldx.2014.04.007. Epub 2014 Jul 3.

PMID:
24998186
10.

Lineage-restricted function of the pluripotency factor NANOG in stratified epithelia.

Piazzolla D, Palla AR, Pantoja C, Cañamero M, de Castro IP, Ortega S, Gómez-López G, Dominguez O, Megías D, Roncador G, Luque-Garcia JL, Fernandez-Tresguerres B, Fernandez AF, Fraga MF, Rodriguez-Justo M, Manzanares M, Sánchez-Carbayo M, García-Pedrero JM, Rodrigo JP, Malumbres M, Serrano M.

Nat Commun. 2014 Jun 30;5:4226. doi: 10.1038/ncomms5226.

PMID:
24979572
11.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

12.

MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9.

Jia AY, Castillo-Martin M, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C.

Br J Cancer. 2014 Jun 10;110(12):2945-54. doi: 10.1038/bjc.2014.245. Epub 2014 May 13.

13.

Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors.

García-Baquero R, Puerta P, Beltran M, Alvarez-Mújica M, Alvarez-Ossorio JL, Sánchez-Carbayo M.

Tumour Biol. 2014 Jun;35(6):5777-86. doi: 10.1007/s13277-014-1767-6. Epub 2014 Feb 28.

PMID:
24577895
14.

Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer.

Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A.

Urol Oncol. 2014 Oct;32(7):1061-8. doi: 10.1016/j.urolonc.2013.10.010. Epub 2014 Jan 9. Review.

PMID:
24411790
15.

The neuroendocrine component in bladder tumors.

Pompas-Veganzones N, Gonzalez-Peramato P, Sanchez-Carbayo M.

Curr Med Chem. 2014;21(9):1117-28. Review.

PMID:
24304278
16.

Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA.

López V, González-Peramato P, Suela J, Serrano A, Algaba F, Cigudosa JC, Vidal A, Bellmunt J, Heredero O, Sánchez-Carbayo M.

J Transl Med. 2013 Aug 1;11:182. doi: 10.1186/1479-5876-11-182.

17.

Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma.

Beltran AL, Ordonez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Kirkali Z, Cheng L, Montironi R, Prieto R, De Alava E.

J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):559-67.

PMID:
23830405
18.

Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization.

Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS, Theodorescu D.

Clin Cancer Res. 2013 Jun 1;19(11):2850-60. doi: 10.1158/1078-0432.CCR-12-3084. Epub 2013 Apr 10.

19.

Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.

De Faveri LE, Hurst CD, Platt FM, Taylor CF, Roulson JA, Sanchez-Carbayo M, Knowles MA, Chapman EJ.

Br J Cancer. 2013 Apr 2;108(6):1368-77. doi: 10.1038/bjc.2013.104.

20.

Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study.

García-Baquero R, Puerta P, Beltran M, Alvarez M, Sacristan R, Alvarez-Ossorio JL, Sánchez-Carbayo M.

J Urol. 2013 Aug;190(2):723-30. doi: 10.1016/j.juro.2013.01.105. Epub 2013 Feb 26.

PMID:
23485510
21.

A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells.

Jia AY, Castillo-Martin M, Domingo-Domenech J, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C.

Am J Pathol. 2013 Apr;182(4):1171-9. doi: 10.1016/j.ajpath.2013.01.006. Epub 2013 Feb 12.

22.

Loss of SPARC in bladder cancer enhances carcinogenesis and progression.

Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D.

J Clin Invest. 2013 Feb;123(2):751-66. doi: 10.1172/JCI64782. Epub 2013 Jan 16. Erratum in: J Clin Invest. 2013 Sep 3;123(9):4089.

23.

A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness.

Grau L, Luque-Garcia JL, González-Peramato P, Theodorescu D, Palou J, Fernandez-Gomez JM, Sánchez-Carbayo M.

PLoS One. 2013;8(1):e53328. doi: 10.1371/journal.pone.0053328. Epub 2013 Jan 8.

24.

Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.

Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Ulhøi BP, Borre M, Ørntoft TF, Dyrskjøt L.

Am J Pathol. 2013 Feb;182(2):339-49. doi: 10.1016/j.ajpath.2012.10.017. Epub 2012 Nov 28.

PMID:
23201130
25.

KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer.

Moya P, Esteban S, Fernandez-Suarez A, Maestro M, Morente M, Sánchez-Carbayo M.

Tumour Biol. 2013 Feb;34(1):471-9. doi: 10.1007/s13277-012-0572-3. Epub 2012 Nov 7.

PMID:
23132294
26.

Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.

Maraver A, Fernández-Marcos PJ, Herranz D, Muñoz-Martin M, Gomez-Lopez G, Cañamero M, Mulero F, Megías D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A, Serrano M.

Cancer Cell. 2012 Aug 14;22(2):222-34. doi: 10.1016/j.ccr.2012.06.014.

27.

Urine epigenomics: a promising path for bladder cancer diagnostics.

Sánchez-Carbayo M.

Expert Rev Mol Diagn. 2012 Jun;12(5):429-32. doi: 10.1586/erm.12.42. No abstract available.

PMID:
22702358
28.

Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.

Alvarez-Múgica M, Fernández-Gómez JM, Cebrian V, Fresno F, Escaf S, Sánchez-Carbayo M.

Eur Urol. 2013 Feb;63(2):364-70. doi: 10.1016/j.eururo.2012.05.050. Epub 2012 Jun 5.

PMID:
22682992
29.

Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.

Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, Malmström PU, Hartmann A, Palou J, Alvarez-Múgica M, Zieger K, Borre M, Ørntoft TF, Dyrskjøt L.

Am J Pathol. 2012 May;180(5):1824-34. doi: 10.1016/j.ajpath.2012.01.023. Epub 2012 Mar 24.

PMID:
22449953
30.

miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.

Puerta-Gil P, García-Baquero R, Jia AY, Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sánchez-Carbayo M.

Am J Pathol. 2012 May;180(5):1808-15. doi: 10.1016/j.ajpath.2012.01.034. Epub 2012 Mar 15.

PMID:
22426337
31.

RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D.

J Clin Invest. 2012 Apr;122(4):1503-18. doi: 10.1172/JCI61392. Epub 2012 Mar 12.

32.

Hypermethylation in bladder cancer: biological pathways and translational applications.

Sánchez-Carbayo M.

Tumour Biol. 2012 Apr;33(2):347-61. doi: 10.1007/s13277-011-0310-2. Epub 2012 Jan 25.

PMID:
22274923
33.

Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer.

Esteban S, Moya P, Fernandez-Suarez A, Vidaurreta M, González-Peramato P, Sánchez-Carbayo M.

Tumour Biol. 2012 Apr;33(2):337-46. doi: 10.1007/s13277-012-0320-8. Epub 2012 Jan 18.

PMID:
22252522
34.

Profilin 1 is a potential biomarker for bladder cancer aggressiveness.

Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M, Vlahou A.

Mol Cell Proteomics. 2012 Apr;11(4):M111.009449. doi: 10.1074/mcp.M111.009449. Epub 2011 Dec 8.

35.

Antibody microarrays as tools for biomarker discovery.

Sanchez-Carbayo M.

Methods Mol Biol. 2011;785:159-82. doi: 10.1007/978-1-61779-286-1_11. Review.

PMID:
21901599
36.

KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients.

Cebrian V, Fierro M, Orenes-Piñero E, Grau L, Moya P, Ecke T, Alvarez M, Gil M, Algaba F, Bellmunt J, Cordon-Cardo C, Catto J, López-Beltrán A, Sánchez-Carbayo M.

Am J Pathol. 2011 Aug;179(2):540-6. doi: 10.1016/j.ajpath.2011.05.009. Epub 2011 Jun 17.

37.

A DNA methylation fingerprint of 1628 human samples.

Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, Villanueva A, Carmona J, Sanchez-Mut JV, Berdasco M, Moreno V, Capella G, Monk D, Ballestar E, Ropero S, Martinez R, Sanchez-Carbayo M, Prosper F, Agirre X, Fraga MF, Graña O, Perez-Jurado L, Mora J, Puig S, Prat J, Badimon L, Puca AA, Meltzer SJ, Lengauer T, Bridgewater J, Bock C, Esteller M.

Genome Res. 2012 Feb;22(2):407-19. doi: 10.1101/gr.119867.110. Epub 2011 May 25.

38.

Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours.

Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M.

Eur Urol. 2011 Jul;60(1):131-40. doi: 10.1016/j.eururo.2011.04.020. Epub 2011 Apr 16.

PMID:
21514719
39.

Systematic quantification of peptides/proteins in urine using selected reaction monitoring.

Selevsek N, Matondo M, Sanchez Carbayo M, Aebersold R, Domon B.

Proteomics. 2011 Mar;11(6):1135-47. doi: 10.1002/pmic.201000599. Epub 2011 Feb 16.

PMID:
21360671
40.

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.

Karni-Schmidt O, Castillo-Martin M, Shen TH, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C, Cordon-Cardo C.

Am J Pathol. 2011 Mar;178(3):1350-60. doi: 10.1016/j.ajpath.2010.11.061. Erratum in: Am J Pathol. 2011 Nov;179(5):2674. HuaiShen, Tian [corrected to Shen, Tian Huai].

41.

Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.

Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A, Heredero O, Palacios A, Urrutia M, Fernández JM, López-Beltrán A, Sánchez-Carbayo M.

J Mol Diagn. 2011 Jan;13(1):29-40. doi: 10.1016/j.jmoldx.2010.11.008. Epub 2010 Dec 23.

42.

Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer.

Said N, Smith S, Sanchez-Carbayo M, Theodorescu D.

J Clin Invest. 2011 Jan;121(1):132-47. doi: 10.1172/JCI42912. Epub 2010 Dec 22.

43.

Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer.

Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D.

Cancer Res. 2011 Feb 1;71(3):832-41. doi: 10.1158/0008-5472.CAN-10-0730. Epub 2010 Dec 10.

44.

Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, Sánchez-Carbayo M.

J Transl Med. 2010 Sep 17;8:86. doi: 10.1186/1479-5876-8-86.

45.

Cyclin D3 gene amplification in bladder carcinoma in situ.

Lopez-Beltran A, Ordóñez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Muñoz E, Cheng L, Montironi R, de Alava E.

Virchows Arch. 2010 Nov;457(5):555-61. doi: 10.1007/s00428-010-0969-6. Epub 2010 Sep 7.

PMID:
20821231
46.

Recommendations for biomarker identification and qualification in clinical proteomics.

Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman RR, Ioannidis JP, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sánchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra TD, Weissinger E, Yamamoto T, Vlahou A.

Sci Transl Med. 2010 Aug 25;2(46):46ps42. doi: 10.1126/scitranslmed.3001249.

PMID:
20739680
47.

Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer.

Alvarez-Múgica M, Cebrian V, Fernández-Gómez JM, Fresno F, Escaf S, Sánchez-Carbayo M.

J Urol. 2010 Oct;184(4):1507-13. doi: 10.1016/j.juro.2010.05.085. Epub 2010 Aug 17.

PMID:
20723929
48.

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.

Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB.

Urol Oncol. 2010 Jul-Aug;28(4):441-8. doi: 10.1016/j.urolonc.2009.11.004.

PMID:
20610281
49.

Galectin-3 expression is associated with bladder cancer progression and clinical outcome.

Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordón-Cardo C, Sánchez-Carbayo M.

Tumour Biol. 2010 Aug;31(4):277-85. doi: 10.1007/s13277-010-0033-9. Epub 2010 Apr 17.

PMID:
20401558
50.

Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens.

Sanchez-Carbayo M.

Tumour Biol. 2010 Apr;31(2):103-12. doi: 10.1007/s13277-009-0014-z. Epub 2010 Jan 21. Review.

PMID:
20358423

Supplemental Content

Loading ...
Support Center